Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [¹⁴C]-Samotolisib in Healthy Subjects
NCT02575703Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of samotolisib in solid tumor, sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3023414 Radioactivity at 144 hours and Fecal Excretion of LY3023414 Radioactivity at 144 hours. Started Oct 2015; status: completed.
02
Drugs
samotolisib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02575703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575703.